Cardiff Oncology, Inc.
CRDF
$1.82
$0.010.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.78% | 5.04% | -18.38% | -34.19% | -26.24% |
| Total Depreciation and Amortization | -3.46% | -5.08% | -4.58% | -3.39% | 124.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.45% | 3.28% | 31.37% | 26.86% | 48.58% |
| Change in Net Operating Assets | -131.69% | -1,491.04% | 218.79% | -176.48% | -82.53% |
| Cash from Operations | 41.88% | -3.62% | 9.77% | -65.30% | -43.82% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 138.28% | 207.89% | -135.37% | -409.25% | -66.76% |
| Cash from Investing | 138.28% | 207.70% | -135.55% | -414.58% | -66.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.22% | -99.66% | -100.00% | -97.20% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.22% | -99.66% | -100.00% | -97.20% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.91% | 94.79% | -294.52% | -813.41% | 498.44% |